Hydrophobic Man-1-P derivatives correct abnormal glycosylation in Type I congenital disorder of glycosylation fibroblasts

Glycobiology

Volumn 15, Issue 11, 2005, Pages 1084-1093

  Eklund, Erik A ^a   Merbouh, Nabyl ^a   Ichikawa, Mie ^a   Nishikawa, Atsushi ^b   Clima, Jessica M ^a   Dorman, James A ^a   Norberg, Thomas ^c   Freeze, Hudson H ^a  

^a BURNHAM INSTITUTE   (United States)

^b TOKYO UNIVERSITY OF AGRICULTURE AND TECHNOLOGY   (Japan)

^c SWEDISH UNIVERSITY OF AGRICULTURAL SCIENCES   (Sweden)

Author keywords

Congenital disorders of glycosylation; GDP Man; Man 1 phosphate phosphomannomutase; N glycosylation

Indexed keywords

DEOXYRIBONUCLEASE I; DIACETOXYMETHYL 2,3,4,6 TETRA O ACETYL ALPHA DEXTRO MANNOPYRANOSYL PHOSPHATE; DIACETOXYMETHYL 2,3,4,6 TETRA O ETHYLOXYCARBONYL ALPHA DEXTRO MANNOPYRANOSYL PHOSPHATE; DOLICHOL PHOSPHATE MANNOSE; GUANOSINE DIPHOSPHATE MANNOSE; HEXOSE PHOSPHATE; LIPOOLIGOSACCHARIDE; MANNOSYLTRANSFERASE; UNCLASSIFIED DRUG;

ARTICLE; CARBOHYDRATE SYNTHESIS; CONGENITAL DISORDER OF GLYCOSYLATION TYPE 1; CONTROLLED STUDY; CYTOTOXICITY; DRUG DEGRADATION; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG STRUCTURE; DRUG SYNTHESIS; FIBROBLAST; HUMAN; HUMAN CELL; HYDROPHOBICITY; PARTICLE SIZE; PRIORITY JOURNAL; PROTEIN GLYCOSYLATION;

CARBOHYDRATE CONFORMATION; CARBOHYDRATE METABOLISM; CARBOHYDRATE-DEFICIENT GLYCOPROTEIN SYNDROME; CELL PROLIFERATION; CULTURE MEDIA; DOSE-RESPONSE RELATIONSHIP, DRUG; FIBROBLASTS; GLYCOSYLATION; HUMANS; MANNOSEPHOSPHATES; MUTATION; PHOSPHOTRANSFERASES (PHOSPHOMUTASES); SUGAR PHOSPHATES; TIME FACTORS;

EID: 27944497414     PISSN: 09596658     EISSN: 14602423     Source Type: Journal    
DOI: 10.1093/glycob/cwj006     Document Type: Article

References (18)

1. Eklund, E.A., Newell, J.W., Sun, L., Seo, N.S., Alper, G., Willert, J., and Freeze, H.H. (2005) Molecular and clinical description of the first US patients with congenital disorder of glycosylation Ig. Mol. Genet. Metab., 84, 25-31.
2. Freeze, H.H. (2001) Update and perspectives on congenital disorders of glycosylation. Glycobiology, 11, 129R-143R.
3. Imbach, T., Schenk, B., Schollen, E., Burda, P., Stutz, A., Grunewald, S., Bailie, N.M., King, M.D., Jaeken, J., Matthijs, G., and others. (2000) Deficiency of dolichol-phosphate-mannose synthase-1 causes congenital disorder of glycosylation type Ie. J. Clin. Invest., 105, 233-239.
4. Jaeken, J. (2003) Komrower lecture. Congenital disorders of glycosylation (CDG): It's all in it? J. Inherit. Metab. Dis., 26, 99-118.
5. Kim, S., Westphal, V., Srikrishna, G., Mehta, D.P., Peterson, S., Filiano, J., Karnes, P.S., Patterson, M.C., and Freeze, H.H. (2000) Dolichol phosphate mannose synthase (DPM1) mutations define congenital disorder of glycosylation Ie (CDG-Ie). J. Clin. Invest., 105, 191-198.
6. Kjaergaard, S., Kristiansson, B., Stibler, H., Freeze, H.H., Schwartz, M., Martinsson, T., and Skovby, F. (1998) Failure of short-term mannose therapy of patients with carbohydrate-deficient glycoprotein syndrome type 1A. Acta Paediatr., 87, 884-888.
7. Marquardt, T. and Denecke, J. (2003) Congenital disorders of glycosylation: Review of their molecular bases, clinical presentations and specific therapies. Eur. J. Pediatr., 162, 359-379.
8. Mayatepek, E. and Kohlmüller, D. (1998) Mannose supplementation in carbohydrate-deficient glycoprotein syndrome type I and phosphomannomutase deficiency. Eur. J. Pediatr., 157, 605-606.
9. Mayatepek, E., Schroder, M., Kohlmuller, D., Bieger, W.P., and Nutzenadel, W. (1997) Continuous mannose infusion in carbohydrate-deficient glycoprotein syndrome type I. Acta Paediatr., 86, 1138-1140.
10. Muus, U., Kranz, C., Marquardt, T., and Meier, C. (2004) Cyclosaligenyl-mannose-1-monophosphates as a new strategy in CDG-Ia therapy: Hydrolysis, mechanistic insights and biological activity. Eur. J. Org. Chem., 2004, 1228-1235.
11. Niehues, R., Hasilik, M., Alton, G., Korner, C., Schiebe-Sukumar, M., Koch, H.G., Zimmer, K.P., Wu, R., Harms, E., Reiter, K., and others. (1998) Carbohydrate-deficient glycoprotein syndrome type Ib. Phosphomannose isomerase deficiency and mannose therapy. J. Clin. Invest., 101, 1414-1420.
12. Nishikawa, A. and Mizuno, S. (2001) The efficiency of N-linked glycosylation of bovine DNase I depends on the Asn-Xaa-Ser/Thr sequence and the tissue of origin. Biochem. J., 355, 245-248.
13. Panneerselvam, K. and Freeze, H.H. (1996) Mannose corrects altered N-glycosylation in carbohydrate-deficient glycoprotein syndrome fibroblasts. J. Clin. Invest., 97, 1478-1487.
14. Rudolf, M.T., Traynor-Kaplan, A.E., and Schultz, C. (1998) A membrane-permeant, bioactivatable derivative of Ins(1,3,4)P3 and its effect on Cl(-)-secretion from T84 cells. Bioorg. Med. Chem. Lett., 8, 1857-1860.
15. Rutschow, S., Thiem, J., Kranz, C., and Marquardt, T. (2002) Membrane-permeant derivatives of mannose-1-phosphate. Bioorg. Med. Chem., 10, 4043-4049.
16. Sarkar, A.K., Brown, J.R., and Esko, J.D. (2000) Synthesis and glycan priming activity of acetylated disaccharides. Carbohydr. Res., 329, 287-300.
17. Schultz, C., Vajanaphanich, M., Hardotunian, A.T., Sammak, P.J., Barrett, K.E., and Tsien, R.Y. (1993) Acetoxymethyl esters of phosphates, enhancement of the permeability and potency of cAMP. J. Biol. Chem., 268, 6316-6322.
18. Van Schaftingen, E. and Jaeken, J. (1995) Phosphomannomutase deficiency is a cause of carbohydrate-deficient glycoprotein syndrome type I. FEBS Lett., 377, 318-320.